Thumbnail Image
Publication

Gut microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging pathogenic mechanisms and therapeutic Implications

Abdelhameed, Farah
; 
Mustafa, Attia
; 
Kite, Chris
; 
Lagojda, Lukasz
; 
Dallaway, Alexander
; 
Than, Nwe Ni
; 
Kassi, Eva
; 
Kyrou, Ioannis
; 
Randeva, Harpal S.
Advisors
Editors
Other Contributors
Affiliation
University Hospitals Coventry and Warwickshire NHS Trust; University of Warwick; Omar Almukhtar University; University of Wolverhampton; University of Chester; University of Sheffield; National and Kapodistrian University of Athens;
EPub Date
Publication Date
2025-03-04
Submitted Date
Collections
Sport and Exercise Sciences
Show all metadata
Files
Thumbnail Image
Article - VoR
Adobe PDF, 1.47 MB
Other Titles
Abstract
Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common cause of chronic liver disease worldwide. Characterized by excessive hepatic fat accumulation, this disease encompasses a spectrum from simple steatosis to more severe forms, including steatohepatitis, fibrosis, and cirrhosis. Emerging evidence highlights the pivotal role of gut dysbiosis in the pathogenesis of MASLD. Dysbiosis disrupts the gut–liver axis, an intricate communication network that regulates metabolic, immune, and barrier functions. Alterations in gut microbiota composition, increased gut permeability, and translocation of pro-inflammatory metabolites/factors have been shown to trigger liver inflammatory and fibrotic cascades, exacerbating hepatic inflammation and injury. Recent studies have identified microbiome signatures associated with MASLD, offering promise as non-invasive diagnostic biomarkers and paving the way for new potential therapeutic strategies targeting gut dysbiosis. This review explores the crucial role of the gut microbiota in MASLD pathogenesis and highlights the need for further targeted research in this field to validate microbial biomarkers and optimize therapeutic strategies. Comprehensive understanding of the gut–liver axis may enable innovative diagnostic and therapeutic approaches, transforming the clinical management of MASLD.
Citation
Abdelhameed, F., Mustafa, A., Kite, C., Lagojda, L., Dallaway, A., Than, N. N., Kassi, E., Kyrou, I., & Randeva, H. S. (2025). Gut microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging pathogenic mechanisms and therapeutic Implications. Livers, 5(1), article-number 11. https://doi.org/10.3390/livers5010011
Publisher
MDPI
Journal
Livers
Research Unit
URI
http://hdl.handle.net/10034/629295
DOI
10.3390/livers5010011
PubMed ID
PubMed Central ID
Type
Article
Language
Description
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Series/Report no.
ISSN
EISSN
2673-4389
ISBN
ISMN
Gov't Doc
Test Link
Sponsors
Unfunded
Additional Links
https://www.mdpi.com/2673-4389/5/1/11